On September 8, 2021 – Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported that Dr. Amit Kumar, Anixa’s Chief Executive Officer, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021 (Press release, Anixa Biosciences, SEP 8, 2021, https://ir.anixa.com/news/detail/983/anixa-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference [SID1234587412]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the presentation, Dr. Kumar will provide an overview of Anixa’s business and highlight recent corporate achievements, including the recent FDA clearance to proceed with clinical trials of its CAR-T based ovarian cancer therapeutic program, as well as anticipated milestones in its breast cancer vaccine clinical trials. Company management will also be available to participate in online one-on-one meetings with conference attendees.
Details of Anixa’s presentation are as follows:
Event: H.C. Wainwright 23rd Annual Global Investment Conference
Date & Time: On demand, beginning 7:00 a.m. ET, Monday, September 13, 2021
Webcast link: View Source
An archive of the webcast will remain available for 90 days after the event.